Sign In

Saturday, March 18, 2017 - 8:00 am to Sunday, March 19, 2017 - 12:00 pm
Add to Calendar

Join us for "Emerging Trends Conference: Emerging Trends in Non-Alcoholic Fatty Liver Disease" in Washington DC March 18-19, 2017

Program Chairs

  • Zobair M. Younossi, MD, MPH, FAASLD
  • Keith D. Lindor, MD, FAASLD

Location

  • Hyatt Regency on Capitol Hill
    Washington DC

Course Description / Needs Statement

The 2017 Emerging Trends Conference will spearhead a development strategy to disseminate new knowledge and treatment options in NAFLD. Major advances in the epidemiology, natural history, pathogenesis and diagnostic modalities have been uncovered although no established treatment has been approved. By facilitating new and exciting translational and therapeutic research in NAFLD, collaborations among clinicians, industry, academic institutions, and public health agencies will be well equipped to deal with this epidemic that threatens our quality of life.

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Recognize the global epidemiology of NAFLD.
  • Evaluate the strength/limitation of different diagnostic and prognostic modalities of NAFLD.
  • Review the current and future treatment of NAFLD.

Continuing Education

  • CME: 11.50 AMA PRA Category 1 Credits
  • Maintenance of Certification (MOC): 11.50 MOC Points

In the schedule below, it should be noted that breakfast will be served at 7 am on both days.

 

Registration Pricing

  • Member $400
  • Trainee & Assoc. Members $200
  • Non-Member $615
    Any physician, scientist, or researcher with doctoral-level training
    who is not employed by Industry (pharma/device/etc.)
  • Trainee & Assoc. Non-Member $250
    Any physician, scientist or researcher in a training program as certified
    by the director of their training program. 
    This category also includes, but is not limited to, the degrees of
    MS, NP, PA, RN, and other related or comparable degrees.
  • Industry $850
    Any Industry (pharma/device/etc.) employee with or without medical training.

Session I: Definition, Diagnosis and Outcomes

Saturday, March 18, 2017
Moderators: Elisabetta Bugianesi, MD, PhD and Stephen H. Caldwell, MD, FAASLD

  • 8:00 am - 8:05 am
    Welcome and Opening Remarks
    Zobair M. Younossi, MD, MPH, FAASLD and Keith D. Lindor, MD, FAASLD
  • 8:05 am - 8:25 am
    Clinical, Epidemiologic, Patient-Reported and Economic Burden of NAFLD
    Zobair M. Younossi, MD, MPH, FAASLD
  • 8:25 am - 8:45 am
    Long Term Outcomes: Mortality and Causes of Death in NAFLD
    Mary E. Rinella, MD, FAASLD
  • 8:45 am - 9:05 am
    Will The Epidemic of NAFLD Be Responsible for the Future Burden of HCC?
    Elisabetta Bugianesi, MD, PhD
  • 9:05 am - 9:15 am
    Q&A

Session II: Metabolic Syndrome and NASH

Saturday, March 18, 2017
Moderators: Lawrence Serfaty, MD and Stephen A. Harrison, MD, FAASLD

  • 9:15 am - 9:35 am
    Is MS the Consequence or Precursor of NASH?
    Giulio Marchesini, MD
  • 9:35 am - 9:55 am
    Insulin Resistance in NAFLD
    Brent A. Tetri, MD, FAASLD
  • 9:55 am - 10:15 am
    Lipid Abnormalities in NAFLD
    Lawrence Serfaty, MD
  • 10:15 am - 10:35 am
    Cardiovascular Diseases and NAFLD
    Francesco Negro, MD
  • 10:35 am - 10:45 am
    Q&A
  • 10:45 am - 10:55 am
    Break

Session III: Pathogenic Mechanisms

Saturday, March 18, 2017
Moderators: Brent A. Tetri, MD, FAASLD and Zachary D. Goodman, MD, PhD, FAASLD

  • 10:55 am - 11:15 am
    The Role of Mitochondria and Endoplasmic Reticulum in NASH Pathogenesis
    Stephen H. Caldwell, MD, FAASLD
  • 11:15 am - 11:35 am
    The Role White Adipose Tissue in NASH
    Vlad Ratziu, MD
  • 11:35 am - 11:55 am
    NAFLD and Microbiome
    Kathleen E. Corey, MD, MPH
  • 11:55 am - 12:15 pm
    Fibrogenesis of NASH: What Is Different About It?
    Scott L. Friedman, MD, FAASLD
  • 12:15 pm - 12:35 pm
    Experimental Models of NAFLD: Do They Represent the Human Disease?
    Manal F. Abdelmalek, MD, MPH, FAASLD
  • 12:35 pm - 12:45 pm
    Q & A
  • 12:45 pm - 1:30 pm
    Lunch

Session IV: Special Topics in NASH

Saturday, March 18, 2017
Moderators: Philippe Mathurin, MD, PhD and Michael R. Charlton, MD

  • 1:30 pm - 1:50 pm
    Racial and Ethnic Differences in Nonalcoholic Fatty Liver Disease
    Arun J. Sanyal, MD, FAASLD
  • 1:50 pm - 2:10 pm
    Nonalcoholic Fatty Liver Disease in Children: Not a Tiny Matter
    Joel E. Lavine, PhD, FAASLD
  • 2:10 pm - 2:30 pm
    NASH and Bariatric Surgery
    Philippe Mathurin, MD, PhD
  • 2:30 pm - 2:50 pm
    NASH and Liver Transplantation
    Michael R. Charlton, MD
  • 2:50 pm - 3:00 pm
    Q & A
  • 3:00 pm - 3:10 pm
    Break

Session V: Oral Presentations

Saturday, March 18, 2017
Moderators: Francesco Negro, MD and Rohit Loomba, MD

  • 3:10 pm - 3:25 pm
    Steatosis, Portal Inflammation and Fibrosis are More Advanced in Younger Children with Non-Alcoholic Fatty Liver Disease (NAFLD) 
    Reham Abdou, MD
  • 3:25 pm - 3:40 pm
    The Association of Histologic Activity with Long Term Outcomes of Patients with Non-alcoholic Fatty Liver Disease
    Maria Stepanova, PhD
  • 3:40 pm - 3:55 pm
    Predicting the Degree of Liver-Biopsy-Confirmes Steatosis and Fibrosis Using Transient Elastography and Magnetic Resonance Imaging-Based Techniques in Adult Patients with Suspected Non-Alcoholic Fatty Liver Disease 
    Stephen A. Harrison, MD, FAASLD
  • 3:55 pm - 4:10 pm
    Impact of a Structured Exercise, Nutrition and Patient Education Program on Short Term Outcomes in Patients with Non-Alcoholic Fatty Liver Disease
    Monica A. Konerman, MD
  • 4:10 pm - 4:25 pm
    VLX103, a New Hepatoselective Investigational Drug Targeting the LPS-TLR4 Pathway in Non-Alcoholic Liver Disease 
    Patrick Colin, BPharm, PhD
  • 4:25 pm - 4:40 pm
    The Comparative Effect of Liraglutide, Elafibranor and Obeticholic Acid on NAFLD Activity Score and Fibrosis Stage in a Diet-Induced Obese Mouse Model of Biopsy-Confirmed Non-Alcoholic Steatohepatitis
    Michael Feigh, MD
  • 4:40 pm - 5:30 pm
    Reception and Poster Viewing

Session VI: Endpoints

Sunday, March 19, 2017
Moderators: Kris V. Kowdley, MD, FAASLD and Naga P. Chalasani, MD

  • 8:00 am - 8:20 am
    Role of Histopathology in the Clinical Research and Clinical Management of Patients with NAFLD
    Zachary D. Goodman, MD, PhD, FAASLD
  • 8:20 am - 8:40 am
    The Role Radiologic Modalities for Diagnosing, Staging and Monitoring NASH
    Rohit Loomba, MD
  • 8:40 am - 9:00 am
    Noninvasive Biomarkers in NASH
    Naga P. Chalasani, MD
  • 9:00 am - 9:20 am
    Serum Fibrosis Markers in NASH
    Quentin M. Anstee, MBBS, PhD
  • 9:20 am - 9:40 am
    What Are the Best Endpoints for the Clinical Trials of NASH: Investigator and Regulatory Perspective
    Kris V. Kowdley, MD, FAASLD
  • 9:40 am - 9:50 am
    Q & A
  • 9:50 am - 10:00 am
    Break

Session VII: Emerging Therapies

Sunday, March 19, 2017
Moderators: Zobair M. Younossi, MD, MPH, FAASLD and Keith D. Lindor, MD, FAASLD

  • 10:00 am - 10:20 am
    Weight Loss and Exercise in NAFLD
    Jacob George, PhD, FAASLD
  • 10:20 am - 10:40 am
    The Current Medical Treatment for Patients with NASH
    Manal F. Abdelmalek, MD, MPH, FAASLD
  • 10:40 am - 11:00 am
    Emerging Therapy for NASH: Non-Antifibrotics
    Stephen A. Harrison, MD, FAASLD
  • 11:00 am - 11:20 am
    Emerging Therapy for NASH: Antifibrotics
    Scott L. Friedman, MD, FAASLD
  • 11:20 am - 11:30 am
    Q & A
  • 11:30 am - 11:50 am
    Summary of the Meeting: What to Do Next?
    Keith D. Lindor, MD, FAASLD
  • 11:50 am - 12:00 pm
    Closing Remarks
    Zobair M. Younossi, MD, MPH, FAASLD
  • 12:00 pm
    Adjourn